LONA – leonabio, inc. (US:NASDAQ)

News

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Athira Pharma (LONA) was upgraded by Zacks Research to "hold".
Athira Pharma (LONA) was downgraded by Wall Street Zen from "hold" to
Athira Pharma (LONA) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Athira Pharma (NASDAQ:LONA) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com